

# Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

## HEC-1-B

RRID:CVCL\_0294

Type: Cell Line

### Proper Citation

RRID:CVCL\_0294

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0294](https://web.expasy.org/cellosaurus/CVCL_0294)

**Proper Citation:** RRID:CVCL\_0294

**Description:** Cell line HEC-1-B is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Type II endometrial adenocarcinoma

**Defining Citation:** [PMID:327080](#), [PMID:833871](#), [PMID:3518877](#), [PMID:4678779](#), [PMID:6163305](#), [PMID:6174649](#), [PMID:6220172](#), [PMID:12227503](#), [PMID:20215515](#), [PMID:20218740](#), [PMID:20944090](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:25877200](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#)

**Comments:** Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** HEC-1-B

**Synonyms:** Hec-1-B, HEC-1B, Hec-1b, HEC1-B, HEC1B, Hec1B

**Cross References:** BTO:BTO\_0003038, CLO:CLO\_0003675, EFO:EFO\_0002192, MCCL:MCC:0000184, CLDB:cl1582, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ATCC:HTB-113, BioGRID\_ORCS\_Cell\_line:420, BioSample:SAMN03471094, BioSample:SAMN03472427, BioSample:SAMN03473077, BioSample:SAMN10987737, cancercellines:CVCL\_0294, CCRID:1101HUM-PUMC000105, CCRID:3101HUMTCHu115, CCRID:4201HUM-CCTCC00129, CCTCC:GDC0129,

Cell\_Model\_Passport:SIDM01241, ChEMBL-Cells:CHEMBL3308662, ChEMBL-Targets:CHEMBL614817, CLS:305095, Cosmic:687552, Cosmic:809131, Cosmic:846178, Cosmic:980635, Cosmic:1070807, Cosmic:1177621, Cosmic:1223486, Cosmic:1241345, Cosmic:1576458, Cosmic:1696757, Cosmic:2030465, DepMap:ACH-000941, GEO:GSM844557, GEO:GSM887070, GEO:GSM888140, IARC\_TP53:1111, IGRhCellID:HEC1B, JCRB:JCRB1193, JCRB:NIHS0480, KCB:KCB 200551YJ, LiGeA:CCLE\_480, PharmacDB:HEC1B\_532\_2019, Progenetix:CVCL\_0294, PubChem\_Cell\_line:CVCL\_0294, Ubigen:YC-C108, Wikidata:Q54882253

**ID:** CVCL\_0294

**Hierarchy:** cvcl\_0293

**Record Creation Time:** 20220427T220324+0000

**Record Last Update:** 20260905T180230+0000

---

## Ratings and Alerts

No rating or validation information has been found for HEC-1-B.

**Warning:** Discontinued: JCRB; NIHS0480

Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 228 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Song L, et al. (2025) Penfluridol targets septin7 to suppress endometrial cancer by septin7-Orai/IP3R-Ca2+-PIK3CA pathway. iScience, 28(1), 111640.

Yu H, et al. (2025) Assessment of NUDT5 in Endometrial Carcinoma: Functional Insights, Prognostic and Therapeutic Implications. Biomedicines, 13(5).

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3864.

Yang Z, et al. (2025) Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma. Cancer research communications, 5(4), 719.

Puleo N, et al. (2025) Identification of a TNIK-CDK9 Axis as a Targetable Strategy for Platinum-Resistant Ovarian Cancer. *Molecular cancer therapeutics*, 24(4), 639.

Wu Z, et al. (2025) Lipid-Metabolism-Related Gene Signature Predicts Prognosis and Immune Microenvironment Alterations in Endometrial Cancer. *Biomedicines*, 13(5).

Liu L, et al. (2024) A negatively charged region within carboxy-terminal domain maintains proper CTCF DNA binding. *iScience*, 27(12), 111452.

Hagiyaama M, et al. (2024) Efficient intracellular drug delivery by co-administration of two antibodies against cell adhesion molecule 1. *Journal of controlled release : official journal of the Controlled Release Society*, 371, 603.

Gong X, et al. (2024) Pyroptosis-associated genes and tumor immune response in endometrial cancer. *Discover oncology*, 15(1), 433.

Lv M, et al. (2024) TSLP enhances progesterin response in endometrial cancer via androgen receptor signal pathway. *British journal of cancer*, 130(4), 585.

Ono M, et al. (2023) Anti-tumor effect of Wasabi component, 6-(methylsulfinyl) hexyl isothiocyanate, against endometrial carcinoma cells. *Discover. Oncology*, 14(1), 9.

Liang C, et al. (2023) Vitexin suppresses the proliferation, angiogenesis and stemness of endometrial cancer through the PI3K/AKT pathway. *Pharmaceutical biology*, 61(1), 581.

Shi R, et al. (2023) Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer. *BMC cancer*, 23(1), 491.

Ruan GY, et al. (2023) An integrated approach of network pharmacology, molecular docking, and experimental verification uncovers kaempferol as the effective modulator of HSD17B1 for treatment of endometrial cancer. *Journal of translational medicine*, 21(1), 204.

Varan C, et al. (2023) Design and Characterization of Carboplatin and Paclitaxel Loaded PCL Filaments for 3D Printed Controlled Release Intrauterine Implants. *Pharmaceutics*, 15(4).

Trujillo L, et al. (2023) Cytotoxic Activity of Amaryllidaceae Plants against Cancer Cells: Biotechnological, In Vitro, and In Silico Approaches. *Molecules (Basel, Switzerland)*, 28(6).

Chen S, et al. (2023) lncRNA XIST/miR-129-2-3p axis targets CCP110 to regulate the proliferation, invasion and migration of endometrial cancer cells. *Experimental and therapeutic medicine*, 25(4), 159.

Meijuan C, et al. (2023) Synaptotagmin-like protein 1 is a potential diagnostic and prognostic biomarker in endometrial cancer based on bioinformatics and experiments. *Journal of ovarian research*, 16(1), 16.

Peterson R, et al. (2023) RPLP1 Is Up-Regulated in Human Adenomyosis and Endometrial Adenocarcinoma Epithelial Cells and Is Essential for Cell Survival and Migration In Vitro. *International journal of molecular sciences*, 24(3).

Zhang C, et al. (2023) Long non-coding RNA BLACAT2/miR-378a-3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma. *Oncology reports*, 49(5).